Opus Genetics (NASDAQ:IRD) Price Target Cut to $8.00 by Analysts at Jones Trading

Opus Genetics (NASDAQ:IRD) had its target price trimmed by Jones Trading from $9.00 to $8.00 in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Opus Genetics in a research report on Tuesday.

Opus Genetics Stock Down 7.3 %

NASDAQ IRD opened at $0.91 on Tuesday. Opus Genetics has a 1 year low of $0.81 and a 1 year high of $1.56. The company has a market capitalization of $29.16 million, a PE ratio of -0.83 and a beta of 0.28. The business has a 50-day simple moving average of $1.07.

Opus Genetics (NASDAQ:IRD) last issued its quarterly earnings data on Monday, March 31st. The company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.93). The business had revenue of $3.40 million during the quarter, compared to the consensus estimate of $11.10 million. Opus Genetics had a negative return on equity of 63.65% and a negative net margin of 324.45%. As a group, equities analysts anticipate that Opus Genetics will post -1.22 EPS for the current year.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.